IRIDEX Study Shows MicroPulse Laser Offers Safer, More Precise Glaucoma Treatment

Reuters
2025/12/08
IRIDEX Study Shows MicroPulse Laser Offers Safer, More Precise Glaucoma Treatment

IRIDEX Corporation announced the publication of a new clinical study in Translational Vision Science & Technology examining the thermal dynamics of transscleral laser treatments for glaucoma. The study, led by Dr. Tomas M. Grippo, utilized advanced computer modeling to compare the tissue heating effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and MicroPulse® transscleral laser therapy (MicroPulse TLT) using IRIDEX's Cyclo G6® Laser and associated delivery devices. Results showed that CW-TSCPC produced a wider and hotter thermal zone compared to MicroPulse TLT, which generated a smaller, more uniform heat distribution and maintained lower peak temperatures. The findings, which have already been published, suggest both techniques share a thermal continuum and may be optimized for different clinical roles in glaucoma management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597358-en) on December 08, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10